Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Nanotechnology-Driven Cell-Based Therapies in Regenerative Medicine

Alzate-Correa D., Lawrence WR., Salazar-Puerta A., Higuita-Castro N., Gallego-Perez D.

Narrative Review on Face & Skin, published in AAPS J (2022) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
AAPS J (2022)
Reported sample size
—
Source database
Europe PMC
PMID
35292878
PMCID
PMC9074705
DOI
10.1208/s12248-022-00692-3
Citations
19

Abstract (original English)

The administration of cells as therapeutic agents has emerged as a novel approach to complement the use of small molecule drugs and other biologics for the treatment of numerous conditions. Although the use of cells for structural and/or functional tissue repair and regeneration provides new avenues to address increasingly complex disease processes, it also faces numerous challenges related to efficacy, safety, and translational potential. Recent advances in nanotechnology-driven cell therapies have the potential to overcome many of these issues through precise modulation of cellular behavior. Here, we describe several approaches that illustrate the use of different nanotechnologies for the optimization of cell therapies and discuss some of the obstacles that need to be overcome to allow for the widespread implementation of nanotechnology-based cell therapies in regenerative medicine.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Regenerative MedicineNanotechnologyCell- and Tissue-Based Therapy

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research